Billionaires Are Betting Billions That We Can Live
Forever
�� OpenAI + Retro Biosciences achieved 50x improvement in cell reprogramming efficiency
�� Longevity funding hit $8.49B in 2024 — up 220% from 2023
�� Bezos, Altman, and Armstrong are racing to add 10 healthy years to human life
⚡ 18 months vs 4-6 years: Insilico Medicine's AI discovered drug candidates in record time at just $150K cost
��
��
50x efficiency gain: OpenAI's GPT-4b micro redesigned Yamanaka factors for stem cell reprogramming
20+ candidates in 3 years: AI platforms generating drug pipelines at unprecedented speed
�� 60-200 molecules tested: vs thousands in traditional pharma R&D per program
��
Jeff Bezos — Altos Labs: $3B to reverse aging through cellular rejuvenation
�� Sam Altman — Retro Bio: $180M seed, now chasing $5B valuation and $1B raise
�� Brian Armstrong — NewLimit: $130M Series B for epigenetic reprogramming
�� Larry Page — Calico: $3.5B+ invested over 11 years (AbbVie partnership ended Nov 2025)
�� Cellular reprogramming: Altos Labs extended mouse lifespan through partial reprogramming (2024)
�� Senolytics working: Unity's UBX1325 showed vision improvements in diabetic patients (NEJM 2025)
�� Alzheimer's trial launching: Retro Bio's autophagy-restoring drug enters clinic end of 2025
�� Aging happens in phases: Stanford found accelerated aging at ages 44 and 60 — targetable intervals
"Biology is too complicatedfor humans to figure outalone. The AImodels showing traction lately workon sequentialdata types, likeprotein sequences. "
— Joe Betts-LaCroix, CEO Retro Biosciences
�� Key insight: Discovery platforms raised $2.65B in 2024 — investors betting on AI infrastructure over single drugs
Market shift: Later-stage VC now 31% of funding — sector moving from hype to execution phase
If you could add 10 healthy years to your life, what would you do with them?
$3B
Altos Labs — largest longevity funding round in history
50x
OpenAI-Retro improvement in stem cell reprogramming efficiency
12-18 mo
Insilico's AI drug discovery timeline (vs 4-6 years traditional)
10 years
The $3B Cellular Rejuvenation Giant
BACKED BY JEFF BEZOS & YURI MILNER
$3B Series A (2022) 300+ Scientists 4 Global Sites
TECH Yamanaka factor partial reprogramming
2024 Mouse lifespan extension published
2025 Human trials initiated (neuro, immune)
M&A Acquired Dorian Therapeutics (May 2025)
OpenAI's Partner in Longevity
FOUNDED BY SAM ALTMAN ($180M SEED) $1B+ Raising Now
5B Target Valuation 10 yrs Lifespan Goal AI GPT-4b micro protein engineering partnership
50X Reprogramming efficiency improvement 2025 Alzheimer's trial launching (autophagy) GOAL "First drug prescribable by end of 2020s"
PHARMA.AI PLATFORM — END-TO-END DISCOVERY
$400M+
Total Raised 20+ Candidates 10 IND Cleared
SPEED 12-18 months target-to-candidate (vs 4-6 yrs)
COST 60-200 molecules tested per program
DEAL Eli Lilly partnership ($100M+ potential)
TRIAL Phase 2a results for IPF drug (ISM001-055)
Coinbase CEO's Epigenetic Bet
BRIAN ARMSTRONG CO-FOUNDER
$130M
Series B (May 2025)
Kleiner Lead Investor Liver First Target
TECH mRNA delivery to aged liver cells
TARGET Alcohol-related liver disease
BACKERS Founders Fund, Khosla Ventures
MISSION Reprogram aged cells to younger states
Google's Aging Moonshot (Pivoting)
ALPHABET SUBSIDIARY — FOUNDED 2013
$3.5B+
Total Investment 5 Clinical Assets 20 Preclinical
UPDATE AbbVie ended 11-year partnership (Nov 2025)
SETBACK Fosigotifator failed Phase 2/3 ALS trial
PIVOT Now independent, focusing on I-O assets
LESSON
Fundamental aging research takes decades
Senolytic Pioneer (Cautionary Tale)
BACKED BY BEZOS & THIEL
UBX1325
Lead Asset NEJM Published 2025 DME Target Disease
WIN Vision improvements in diabetic patients
MISS Phase 2b ASPIRE missed primary endpoint
2025 Stockholders approved liquidation (Sept)
LESSON
Local delivery may not address systemic aging
AI + Human Aging Data
IPO'D ON NASDAQ (OCT 2024)
$297M+
Total Raised $238M
IPO Proceeds 50 yrs Aging Cohorts
DATA Proprietary human longevity datasets
DEAL Novartis $550M milestone deal (Dec 2024)
SETBACK Azelaprag discontinued (liver issues)
STOCK Down ~80% since IPO — high risk space
Blueprint Protocol — The Human Guinea Pig
$60M RAISED (NOV 2024) — KIM K & PARIS
HILTON INVESTED
$2M/yr Personal Spend 40+ Daily Supps 70+ Organs Measured
CLAIM Biological age 5.1 years younger
PACE 0.66 years aging per chronological year
CAVEAT Experts dispute 31-year reversal claim
MODEL Blueprint products now commercial
Wearables & Prevention Platforms
ŌURA — $200M SERIES D (OCT 2024)
& Recovery
Users
Investor FUNCTION HEALTH — $53M SERIES A 100+ Biomarkers a16z Backed Prevention Focus
HEALTH — 100K+ WAITLIST
�� Loyal — $125M raised: First FDA dog lifespan drug, paving human pathway
�� Rubedo Life Sciences — $52M: AI-driven senolytic discovery (ALEMBIC platform)
�� Juvenescence — $76M: AI-enabled therapeutics for healthy lifespan
�� Shift Bioscience — $18M: AI cell simulation platform for aging interventions
01 AI is the unlock: 50x efficiency gains, 18month drug discovery — biology is now a data problem
02 Billionaire conviction: $8.49B in 2024 funding — Bezos, Altman, Armstrong betting personal fortunes
03 Execution phase: Clinical trials launching, real data coming — hype becoming reality